The IV NAD+ evidence, reviewed in full: sparse, small and uncontrolled — a new review grades the drip honestly

Edited by Samael A. Tejada, Founder & Editor-in-Chief

This site covers IV therapy every day, including its genuine promise — and this is the other half of honest coverage. NAD+ biology is real, mitochondrial, and important. The leap from that biology to a recurring four-figure drip is, on the full human record a specialist journal just assembled, unproven. Readers deserve both sentences in the same story.

What did the review actually find in the human literature?

Searching PubMed and Google Scholar for 2018 to March 2026, the authors included human clinical data on IV NAD+ and IV NAD+ precursors plus directly relevant mechanistic and safety evidence. What exists is thin: primarily small uncontrolled studies, observational investigations and isolated case reports. Short-term administration was associated with transient increases in circulating NAD+ and changes in selected biomarkers of oxidative stress, inflammation and cellular metabolism, and limited exploratory reports described self-reported improvements in sleep and neurologic symptoms. The review is explicit that small samples, absent placebo controls, heterogeneous methods and short follow-up leave the clinical significance of all of it uncertain.

Does NAD+ even decline with healthy aging?

One premise of the drip deserves its own paragraph. The review notes that recent large-scale human data indicate whole-blood NAD+ concentrations do not decline with healthy aging per se, once disease burden and comorbidity are accounted for — a finding echoed by a 2026 Redox Biology study that measured NAD and glutathione metabolites in healthy people aged 18 to 70 with a standardized assay and found levels unchanged during aging. That does not make NAD+ unimportant, and tissue levels may differ from blood. It does mean 'your NAD+ falls because you are older, so refill it' is a marketing simplification the current human data do not support as stated.

How should a reader weigh an IV NAD+ offer today?

By the review's own grading: mechanistic rationale, yes; demonstrated clinical benefit, no; long-term safety, unknown. Reported adverse effects — nausea, cramping, flushing, chest discomfort — are usually transient, but 'usually transient in small short studies' is not a safety record. The review also flags that it remains uncertain how much infused NAD+ enters cells intact versus being broken down outside cells into building blocks the body reassembles — the same salvage pathway oral precursors use — so IV superiority over oral routes is asserted by sellers, not demonstrated. Larger randomized controlled trials with standardized protocols and meaningful endpoints are, in the authors' words, required before IV NAD+ can be considered evidence-based practice. Until then, an informed customer is one who knows they are buying an experiment, priced accordingly in their own mind.

Where the evidence stands

• Established: NAD+ is a coenzyme essential to mitochondrial function, DNA repair and stress-response signaling, involved in more than 500 enzymatic reactions; and large-scale human data find whole-blood NAD+ does not decline with healthy aging itself once disease burden is accounted for.
• Preliminary: The human IV NAD+ literature (Frontiers in Aging narrative review, literature Jan 2018–Mar 2026) consists mainly of small uncontrolled studies, observational reports and case reports, with transient NAD+ rises, selected biomarker changes and exploratory self-reported improvements of uncertain clinical significance; adverse effects include nausea, cramping, flushing and chest discomfort.
• Absent: Randomized placebo-controlled trials of IV NAD+, demonstrated superiority over oral precursors, standardized dosing, and long-term safety data — all identified by the review as missing.